Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions

Children with immune thrombocytopenia (ITP) are often managed using a watch‐and‐wait approach to avoid conventional treatment that may be poorly tolerated. However, in some patients, this approach may lead to lifestyle restrictions due to risk of injury‐related bleeding. Eltrombopag is a well‐tolera...

Descripción completa

Detalles Bibliográficos
Autor principal: Bergmann, Shayla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628223/
https://www.ncbi.nlm.nih.gov/pubmed/29026567
http://dx.doi.org/10.1002/ccr3.1086
_version_ 1783268839302103040
author Bergmann, Shayla
author_facet Bergmann, Shayla
author_sort Bergmann, Shayla
collection PubMed
description Children with immune thrombocytopenia (ITP) are often managed using a watch‐and‐wait approach to avoid conventional treatment that may be poorly tolerated. However, in some patients, this approach may lead to lifestyle restrictions due to risk of injury‐related bleeding. Eltrombopag is a well‐tolerated new option that may help these children.
format Online
Article
Text
id pubmed-5628223
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56282232017-10-12 Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions Bergmann, Shayla Clin Case Rep Case Reports Children with immune thrombocytopenia (ITP) are often managed using a watch‐and‐wait approach to avoid conventional treatment that may be poorly tolerated. However, in some patients, this approach may lead to lifestyle restrictions due to risk of injury‐related bleeding. Eltrombopag is a well‐tolerated new option that may help these children. John Wiley and Sons Inc. 2017-09-01 /pmc/articles/PMC5628223/ /pubmed/29026567 http://dx.doi.org/10.1002/ccr3.1086 Text en © 2017 The Author. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Bergmann, Shayla
Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions
title Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions
title_full Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions
title_fullStr Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions
title_full_unstemmed Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions
title_short Proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions
title_sort proactive use of eltrombopag before the onset of clinical bleeding in two children with immune thrombocytopenia and lifestyle restrictions
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628223/
https://www.ncbi.nlm.nih.gov/pubmed/29026567
http://dx.doi.org/10.1002/ccr3.1086
work_keys_str_mv AT bergmannshayla proactiveuseofeltrombopagbeforetheonsetofclinicalbleedingintwochildrenwithimmunethrombocytopeniaandlifestylerestrictions

Ejemplares similares